NCT00064610View on ClinicalTrials.gov

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

December 31, 2004

Conditions
Prostatic Neoplasms
Interventions
DRUG

VELCADE TM (bortezomib) for Injection

Trial Locations (4)

10032

Columbia-Presbyterian Hospital, New York

37232

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic Foundation, Cleveland

90048

Cedars Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00064610 - Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer | Biotech Hunter | Biotech Hunter